Tumor-Derived IL33 Promotes Tissue-Resident CD8(+) T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy.

Chen L, Sun R, Xu J, Zhai W, Zhang D, Yang M, Yue C, Chen Y, Li S, Turnquist H, Jiang J, Lu B
Cancer Immunol Res. 2020 Nov;8(11):1381-1392. doi: 10.1158/2326-6066.CIR-19-1024. Epub 2020 Sep 11. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.